PFAS linkage
- PFAS chemicals can interact with endocrine, immune, and metabolic systems that are relevant to breast cancer research.
- Studies have examined PFAS exposure in relation to breast cancer risk, age at diagnosis, hormone-related pathways, and breast cancer subtypes, with evidence still developing.
- Intake review focuses on exposure duration, diagnosis details, receptor status, family history, and whether exposure occurred during sensitive life stages.
Breast cancer symptoms
- A new breast lump, thickening, or area that feels different
- Change in breast size, shape, skin texture, or nipple appearance
- Nipple discharge, especially if bloody or one-sided
- Breast or nipple pain that persists
- Swollen lymph nodes under the arm or near the collarbone
Diagnosis and medical records
- Diagnostic mammogram, ultrasound, or breast MRI
- Core needle biopsy or surgical biopsy
- Pathology testing for ER, PR, HER2, grade, and tumor type
- Staging scans, genetic testing, or genomic tumor assays when appropriate
Treatment options
- Lumpectomy or mastectomy with lymph-node evaluation
- Radiation therapy after breast-conserving surgery or for selected higher-risk cases
- Chemotherapy, endocrine therapy, HER2-targeted therapy, immunotherapy, or CDK4/6 inhibitors depending on subtype
- Reconstruction, survivorship care, and monitoring for recurrence
What patients should gather for intake
- Save biopsy reports, receptor-status results, surgical pathology, oncology notes, and treatment summaries.
- Record family history and any genetic testing, but also document exposure history independently.
- Include residential, occupational, military, airport, firefighting, or industrial exposure details.
Medical and attorney advertising notice. This page is for general information only and is not medical advice. Talk with your treating clinician about diagnosis and treatment. Submitting an intake form does not create an attorney-client relationship, and cases may be referred to qualified national PFAS co-counsel.